{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,12,22]],"date-time":"2022-12-22T21:51:35Z","timestamp":1671745895616},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[1990,7,1]],"date-time":"1990-07-01T00:00:00Z","timestamp":646790400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[1990,7]]},"DOI":"10.1007\/bf02897233","type":"journal-article","created":{"date-parts":[[2008,4,29]],"date-time":"2008-04-29T13:51:49Z","timestamp":1209477109000},"page":"293-296","source":"Crossref","is-referenced-by-count":6,"title":["4\u2032-O-Tetrahydropyranyl-doxorubicin in advanced breast cancer: a phase II study"],"prefix":"10.1007","volume":"26","author":[{"given":"Hellmut","family":"Samonigg","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne-Katrin","family":"Kasparek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Herbert","family":"St\u00f6ger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marianne","family":"Schmid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernd","family":"Eber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerhard","family":"Stark","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Viktor","family":"Weinrauch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karl","family":"Pfeiffer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Smola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Steindorfer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Lechner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"BF02897233_CR1","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/BF00174163","volume":"3","author":"JC Allegra","year":"1985","unstructured":"Allegra JC, Woodcock T, Woolf S (1985) A randomized trial comparing mitoxantrone with doxorubicin in patients with stage IV breast cancer. Invest New Drugs 3: 153\u2013161","journal-title":"Invest New Drugs"},{"key":"BF02897233_CR2","first-page":"1181","volume":"70","author":"M Andersson","year":"1986","unstructured":"Andersson M, Daugaard S, Maase H von der (1986) Doxorubicin versus mitomycin versus doxorubicin plus mitomycin in advanced breast cancer: a randomized study. Cancer Treat Rep 70: 1181\u20131186","journal-title":"Cancer Treat Rep"},{"key":"BF02897233_CR3","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/BF00174162","volume":"3","author":"JD Cowan","year":"1985","unstructured":"Cowan JD, Osborne CK, Neidhart JA (1985) A randomized trial of doxorubicin, mitoxantrone and bisantrene in advanced breast cancer (a Southwest Oncology Group Study). Invest New Drugs 3: 149\u2013152","journal-title":"Invest New Drugs"},{"key":"BF02897233_CR4","first-page":"15","volume":"211","author":"D Dantchev","year":"1983","unstructured":"Dantchev D, Bourut C, Maral R (1983) Cardiotoxicity and alopecia of 12 different anthracyclines and 1 anthracycline in the golden hamster model. Proc Int Congr Chemother (Vienna) 211: 15\u201319","journal-title":"Proc Int Congr Chemother (Vienna)"},{"key":"BF02897233_CR5","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1002\/sim.4780020402","volume":"2","author":"PM Fayers","year":"1983","unstructured":"Fayers PM, Jones DR (1983) Measuring and analysing quality of life in cancer clinical trials: a review. Stat Med 2: 429\u2013446","journal-title":"Stat Med"},{"key":"BF02897233_CR6","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/0014-2964(77)90234-1","volume":"13","author":"JL Hayward","year":"1977","unstructured":"Hayward JL, Rubens RD, Carbone PP (1977) (1978) Assessment of response to therapy in advanced breast cancer. Eur J Cancer 13: 89\u201394 (with addendum, Eur J Cancer 14: 1291\u20131292)","journal-title":"Eur J Cancer"},{"key":"BF02897233_CR7","first-page":"101","volume":"2","author":"B Hoogstraten","year":"1979","unstructured":"Hoogstraten B, Fabian C (1979) A reappraisal of single drugs in advanced breast cancer. Cancer Clin Trials 2: 101\u2013109","journal-title":"Cancer Clin Trials"},{"issue":"2","key":"BF02897233_CR8","first-page":"368","volume":"13","author":"K Kimura","year":"1986","unstructured":"Kimura K (1986) A phase II study of (2\u2033R)-4\u2032-O-tetrahydropyranyladriamycin (THP) in patients with hematological malignancies. Jpn J Cancer Chemother 13 (2): 368\u2013375","journal-title":"Jpn J Cancer Chemother"},{"issue":"3","key":"BF02897233_CR9","doi-asserted-by":"crossref","first-page":"312","DOI":"10.7164\/antibiotics.36.312","volume":"36","author":"S Kunimoto","year":"1983","unstructured":"Kunimoto S, Miura K, Takahashi Y, (1983) Rapid uptake by cultured tumor cells and intracellular behavior of 4\u2032-O-tetrahydropyranyladriamycin. J Antibiot 36 (3): 312\u2013317","journal-title":"J Antibiot"},{"key":"BF02897233_CR10","volume-title":"Statistical methods for survival data analysis","author":"ET Lee","year":"1980","unstructured":"Lee ET (1980) Statistical methods for survival data analysis. Life-time Learning, Belmont, California"},{"key":"BF02897233_CR11","first-page":"134","volume":"10","author":"H Majima","year":"1983","unstructured":"Majima H (1983) Exploratory clinical study of 4\u2032-O-tetrahydropyranyl doxorubicin (THP-ADM), phase I. Gan To Kagaku Ryoho 10: 134\u2013140","journal-title":"Gan To Kagaku Ryoho"},{"key":"BF02897233_CR12","first-page":"542","volume":"13","author":"H Majima","year":"1986","unstructured":"Majima H, Iguchi H, Tone H (1986) Pharmacokinetic studies on THP-ADM (tetrahydropyranyl-Adriamycin). Jpn J Cancer Chemother 13: 542\u2013548","journal-title":"Jpn J Cancer Chemother"},{"key":"BF02897233_CR13","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1002\/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6","volume":"47","author":"AB Miller","year":"1981","unstructured":"Miller AB, Hoogstraten B, Staquet M (1981) Reporting results of cancer treatment. Cancer 47: 207\u2013214","journal-title":"Cancer"},{"key":"BF02897233_CR14","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/BF00390491","volume":"114","author":"AB Miller","year":"1988","unstructured":"Miller AB, Scheulen ME, Kleeberg UR (1988) Phase I study of pirarubicin. J Cancer Res Clin Oncol 114: 91\u201394","journal-title":"J Cancer Res Clin Oncol"},{"key":"BF02897233_CR15","first-page":"138","volume":"11","author":"H Nakady","year":"1984","unstructured":"Nakady H, Ogawa M, Miyamoto H, (1984) Phase II study of 4\u2032-O-tetrahydropyranyladriamycin (THP-ADM). Jpn J Cancer Chemother 11: 138\u2013142","journal-title":"Jpn J Cancer Chemother"},{"key":"BF02897233_CR16","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1200\/JCO.1986.4.5.672","volume":"4","author":"JA Neidhard","year":"1986","unstructured":"Neidhard JA, Gochnoiur D, Roach R (1986) A comparison of mitoxantrone and doxorubicin in breast cancer. J Clin Oncol 4: 672\u2013677","journal-title":"J Clin Oncol"},{"key":"BF02897233_CR17","first-page":"129","volume":"10","author":"M Ogawa","year":"1983","unstructured":"Ogawa M, Miyamoto H, Inagari J (1983) Phase I clinical trial of a new anthracycline, 4\u2032-O-tetrahydropyranyl-Adriamycin. Gan To Kagaku Ryoho 10: 129\u2013133","journal-title":"Gan To Kagaku Ryoho"},{"key":"BF02897233_CR18","first-page":"1060","volume":"13","author":"T Saito","year":"1986","unstructured":"Saito T, Kasai Y, Wakui A (1986) Phase II study of (2\u2033R)-4\u2032-O-tetrahydropyranyladriamycin. Jpn J Cancer Chemother 13: 1060\u20131069","journal-title":"Jpn J Cancer Chemother"},{"issue":"6","key":"BF02897233_CR19","first-page":"829","volume":"74","author":"M Tanaka","year":"1983","unstructured":"Tanaka M, Yoshida S, Kimura K (1983) Mechanism of inhibition of DNA polymerases by 4-epiadriamycin and 4\u2032-O-tetrahydropyranyladriamycin. Jpn J Cancer Res 74 (6): 829\u2013836","journal-title":"Jpn J Cancer Res"},{"issue":"1\u20133","key":"BF02897233_CR20","first-page":"257","volume":"12","author":"H Tapiero","year":"1986","unstructured":"Tapiero H, Munck JN, Fourcade A (1986) Relationship between the intracellular accumulation of anthracyclines and effectiveness in vitro and in vivo. Drugs Expl Clin Res 12 (1\u20133): 257\u2013264","journal-title":"Drugs Expl Clin Res"},{"key":"BF02897233_CR21","first-page":"1594","volume":"66","author":"SG Taylor","year":"1982","unstructured":"Taylor SG, Gelber RD (1982) Experience of the Eastern Cooperative Oncology Group with doxorubicin as a single agent in patients with previously untreated breast cancer. Cancer Treat Rep 66: 1594\u20131595","journal-title":"Cancer Treat Rep"},{"key":"BF02897233_CR22","first-page":"1462","volume":"42","author":"T Tsuruo","year":"1982","unstructured":"Tsuruo T, Iida H, Tsukagoshi S (1982) 4\u2032-O-Tetrahydropyranyladriamycin as a potential new antitumor agent. Cancer Res 42: 1462\u20131467","journal-title":"Cancer Res"},{"key":"BF02897233_CR23","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.7164\/antibiotics.32.1082","volume":"10","author":"H Umezawa","year":"1979","unstructured":"Umezawa H, Takahashi Y, Kinoshita M, (1979) Tetrahydropyranyl derivatives of daunomycin and Adriamycin. J Antibiot 10: 1082\u20131084","journal-title":"J Antibiot"},{"key":"BF02897233_CR24","first-page":"118","volume":"12","author":"A Wakui","year":"1985","unstructured":"Wakui A, Yokoyama M, Konno K, (1985) Phase I trial of 4\u2032-O-tetrahydropyranyl-doroxubicin (THP), a multiinstitutional cooperative study. Gan To Kagaku Ryoho 12: 118\u2013124","journal-title":"Gan To Kagaku Ryoho"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF02897233.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/BF02897233\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF02897233","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,22]],"date-time":"2019-05-22T17:30:33Z","timestamp":1558546233000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/BF02897233"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1990,7]]},"references-count":24,"journal-issue":{"issue":"4","published-print":{"date-parts":[[1990,7]]}},"alternative-id":["BF02897233"],"URL":"https:\/\/doi.org\/10.1007\/bf02897233","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[1990,7]]}}}